It had been reported that ITGAV was a promising therapeutic target for esophageal squamous cell carcinoma (ESCC), as indomethacin can inhibit ESCC growth by binding to ITGAV, promoting SYVN1-mediated ubiquitination of ITGAV, and enhancing cytotoxic CD8+ T cell responses (15). Here, CD8A is linked to esophageal squamous cell carcinoma.